"We are delighted to commercially launch the Libertas TR, demonstrating our continued commitment to developing new implant options to further expand our hip portfolio" says Ashesh Shah, CEO, Maxx Orthopedics.
NORRISTOWN, Pa. (PRWEB) June 25, 2020
Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, announced today the commercial launch and first successful surgeries of its new Libertas® Taper Reduced Uncemented Femoral Stem, the latest addition to its hip system.
The Libertas Taper Reduced Uncemented Femoral Stem (Libertas TR®) is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate patient specific anatomic requirements and are compatible with Maxx’s existing Libertas Femoral Heads as well as the Libertas Acetabular Cup System. The proximal Ti-GrowthC coating on the implant surface is designed to promote biological integration with the bone to achieve longer-term stability, while the geometry of the stem aids in providing a better fit for proximal and distal mismatches.
Dr. Sridhar Durbhakula of OrthoBethesda, in Bethesda, MD and a member of the Libertas TR design team, performed the first cases. He reports, “I have enjoyed working with the Maxx Orthopedics development team in designing this new stem choice. The Libertas TR rounds out their comprehensive array of options for primary total hip arthroplasty. The reduced distal taper minimizes fracture risk and allows optimal proximal fixation, without ever getting caught up distally. The smaller neck length and variable offset options allows accuracy in achieving proper leg length and femoral offset for all patient anatomy, including smaller female patients. The newer generation of instrumentation affords a minimally invasive technique for surgical efficiency. I couldn’t be more excited about the Libertas TR stem!”
“We are delighted to commercially launch the Libertas TR, demonstrating our continued commitment to developing new implant options to further expand our hip portfolio. It is in limited release now, and we expect full commercial release within 3 months. As a company this launch is particularly invigorating as we continue to battle the challenges posed by COVID-19,” says Ashesh Shah, CEO, Maxx Orthopedics.
The Libertas Hip System is a total hip replacement system engineered for providing patients with mechanical and biological stability to help restore mobility. The variety of component and size options enable surgeons to provide patients with a robust hip arthroplasty solution without compromise.
The Libertas Total Hip System is globally available. For additional information, please visit http://www.maxxortho.com or download the MaxxOrtho mobile app.
About Maxx Orthopedics
Maxx Orthopedics is the manufacturer of the Freedom Knee® System, Libertas® Total Hip System and Freedom QRS™ System. The Company develops and markets innovative orthopedic medical devices with a focus on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical, Pvt. Ltd., is the parent company of Maxx Orthopedics, Inc.